Loading...
•
Jun 30, 2025
AbbVie Q2 2025 Earnings Report
AbbVie reported its second-quarter 2025 financial results.
Key Takeaways
AbbVie delivered solid results in Q2 2025 with revenue growth driven by its immunology and neuroscience portfolios, despite ongoing declines in Humira sales and aesthetics.
Total net revenue reached $15.423 billion, up from $14.462 billion in Q2 2024.
Adjusted EPS rose to $2.97 while GAAP EPS was $0.52 due to milestone expenses.
Immunology was the top-performing segment with $7.631 billion in revenue.
Skyrizi and Rinvoq significantly offset Humira’s revenue decline.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
AbbVie raised its full-year 2025 adjusted EPS guidance to $11.88 - $12.08.
Positive Outlook
- Raised full-year 2025 adjusted EPS guidance.
- Strong performance from Skyrizi and Rinvoq.
- Improved clinical data across several pipeline programs.
- Regulatory approval of new indications and therapies.
- Momentum in neuroscience and oncology portfolios.
Challenges Ahead
- Continued decline in Humira revenue.
- Aesthetics portfolio saw an 8.1% revenue drop.
- High milestone-related expenses impacted GAAP EPS.
- Tax rate increased significantly on a GAAP basis.
- International eye care and aesthetics sales declined.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...